[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Suzhou UgeneX Therapeutics Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100616918",false,"NCT07311863","UGX202 Injection in Patients With Advanced Retinitis Pigmentosa","Study to Evaluate the Safety and Preliminary Efficacy of UGX202 Injection in Patients With Advanced Retinitis Pigmentosa","Inclusion Criteria:\n\n* Provide written informed consent form (ICF).\n* Age ≥18 years at ICF signing.\n* Diagnosed as non-syndromic RP；\n* BCVA \\> logMAR 1.9 (assessed by FrACT) in the study eye.\n* Confirmation of preserved memory of visual experience\n* Spherical equivalent between -9D and +6D.\n\nExclusion Criteria:\n\n* Prior gene therapy in either eye.\n* Received any interventional investigational drug within 90 days prior to screening.\n* Any Study eye disease or systemic disease judged by the investigator to affect visual function assessment.\n* Hypersensitivity to corticosteroids, intolerance to corticosteroid regimen, active concurrent infection contraindicating treatment.\n* History or tendency of psychiatric disorders impacting safety and\u002For efficacy assessment.\n* Any other factor deemed unsuitable by the investigator.","ALL","18 Years",{"count":18,"type":19},6,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.",[25],"Retinitis Pigmentosa (RP)",[27,28,29,30,31],"UGX202","UGENEXIIT002","retinitis pigmentosa","RP","AAV","NOT_YET_RECRUITING","2025-12-16",{"date":35,"type":36},"2025-12-31","ACTUAL",{"date":38,"type":19},"2026-01",{"date":40,"type":19},"2027-03",{"name":42,"class":43},"Suzhou UgeneX Therapeutics Co., Ltd.","OTHER",""]